Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
I/II Study of cicimetinib plus SG001 in advanced solid tumors
CTR20233821Phase 2Active
- Sponsor
- Shanghai Institute of Materia Medica
- Start
- Dec 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cicimetinib, PBI-1308 in Nonhematologic neoplasms, sponsored by Shanghai Institute of Materia Medica. Started Dec 2023; status: active.
02
Drugs
cicimetinibPBI-1308
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20233821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233821.